Efficacy of @entity41059 treatment in XXXX with stage IIIb/IV @entity1149 .

@entity1 @entity137 @entity1910 @entity470 @entity5 @entity294 @entity1149 @entity41059
BACKGROUND: To evaluate the efficacy and safety of @entity41059 - an orally administered, highly potent selective inhibitor of @entity470 ( @entity470 ) and its active mutations, in the treatment of @entity1 with advanced @entity1149 ( @entity1149 ). METHODS: A total of 101 @entity1 with stage IIIb/IV @entity1149 were treated with 125   mg @entity41059 three times a day until disease progression or intolerable @entity137 . Response rate was evaluated using response evaluation criteria in solid @entity5 and progression-free survival (PFS) was collected. RESULTS: The overall response rate (ORR) and disease control rate (DCR) were 37.6% (38/101) and 79.2% (80/101), respectively. The median PFS was 6.5 months. Multivariate analysis showed that female gender (P= 0.048, 95% confidence interval [CI] 1.010-6.016) and occurrence of @entity1910 (P= 0.002, 95% CI 1.667-9.809) were the independent predictive factors for ORR, while a performance status (PS) score of 0-1 (P= 0.001, 95% CI 0.024-0.402) and @entity1910 (P= 0.042, 95% CI 1.089-76.557) were the independent predictive factors for DCR. In addition, PS scores of 0-1 (P <0.001, 95% CI 0.135-0.509), and non-smoking (P= 0.017, 95% CI 0.342-0.900) were found to be independent influencing factors for PFS. Moreover, @entity1 with @entity470 mutations had better PFS than @entity1 with wild type @entity470 , while @entity1 with @entity470 exon 19 deletion had better survival than those with @entity470 exon 21 mutation. The most common adverse effects of @entity41059 were @entity1910 (35.6%) and @entity294 (17.8%), which was tolerable. CONCLUSION: Treatment of stage IIIb/IV @entity1149 @entity1 with @entity41059 was effective and tolerable, specifically in @entity1 with @entity470 mutation.
